Enlivex Therapeutics Ltd. — FY 2018 Form 20-F
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing, not a quarterly report; it does not provide standalone fourth-quarter results. Unless noted otherwise, financial amounts are U.S. dollars in thousands. The audited statements reflect Enlivex Therapeutics R&D Ltd. as the accounting predecessor, not pre-merger Bioblast.
Business context
Enlivex is a clinical-stage immunotherapy company developing Allocetra, an allogeneic cell therapy intended to rebalance immune responses. Target areas include complications after hematopoietic stem-cell transplantation (HSCT), sepsis-related organ dysfunction, and potential combinations with cancer immunotherapies. The company had no approved products and generated no product revenue in 2018.
Financial results and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4,255 | $1,691 |
| General and administrative expense | $1,044 | $480 |
| Operating loss | $(5,299) | $(2,171) |
| Net loss | $(4,242) | $(2,504) |
| Comprehensive loss | $(4,990) | $(2,168) |
| Basic and diluted loss per share | $(1.40) | $(0.94) |
| Net cash used in operating activities | $(3,161) | $(2,304) |
| Net cash used in investing activities | $(533) | $(130) |
| Net cash provided by financing activities | $5,194 | $8,055 |
- Drivers: R&D expense increased 152%, primarily from higher salaries, stock-based compensation, preclinical work and materials. G&A increased 118%, including higher salaries, professional fees and stock compensation.
- Financial items: Net financial income was $1,057 in 2018, versus net financial expense of $333 in 2017. The 2018 result included $790 of net foreign-exchange gains, $132 of warrant fair-value income and $138 of interest income. Foreign-currency translation produced a $748 comprehensive loss, versus a $336 gain in 2017.
- Balance sheet at December 31, 2018: Cash and cash equivalents were $9,736; short-term deposits were $40; current assets were $10,277; current liabilities were $1,130; and working capital was approximately $9,147. Total assets were $11,034 and total liabilities were $1,328. The $192 warrant liability was the principal non-current liability; the filing reports no long-term debt obligations.
- Funding and runway: The company reported a $16,289 accumulated deficit and recurring losses. Management estimated existing resources would fund planned operations through approximately Q2 2020, while stating that substantial additional financing would be needed. The filing warns that failure to raise capital could create substantial doubt about continuing operations beyond that period.
- Margins: Not meaningful because the company had no revenue.
Material changes and subsequent events
- R&D spending and operating cash use rose substantially year over year; cash financing fell from $8,055 in 2017 to $5,194 in 2018. The 2018 financing was a Series C preferred-stock issuance, net of issuance costs.
- After year-end, on March 25/26, 2019, Enlivex R&D merged into Bioblast Pharma in a reverse recapitalization. Enlivex R&D was the accounting acquirer; Bioblast changed its name to Enlivex Therapeutics Ltd., and the combined company continued Nasdaq listing under ENLV. The filing gives differing closing-date references that investors should reconcile.
- The filing describes a concurrent private placement. Its summary reports 682,631 shares at $12.25 per share; the unaudited pro forma section instead reflects 437,733 shares for $5,362. Post-merger ownership is reported approximately as 89.1% former Enlivex R&D holders, 4.016% former Bioblast holders and 6.74% placement investors.
- The merger was accounted for as a reverse recapitalization, so the audited historical results are those of Enlivex R&D. The pro forma combined financial information is unaudited and illustrative, not a forecast.
Outlook, commentary and risks
- Development plans: Subject to regulatory approvals, the company planned Phase II/III study enrollment of up to 60 patients for prevention of post-HSCT complications and a Phase II study of up to 40 steroid-refractory GvHD patients, targeted for early 2020. A 10-patient Phase Ib sepsis trial began in Q1 2019; a subsequent 40–50 patient study was planned, subject to successful completion. These are plans, not guidance on financial results.
- Clinical evidence: Enlivex reported favorable Phase IIa HSCT findings from 13 patients; none of the six patients treated at the two highest doses developed grade II–IV GvHD, and their average hospital stay was 21 days versus 41 days in historical data. The small sample and historical comparator limit conclusions. Sepsis and solid-tumor results cited were preclinical.
- Regulatory status: Allocetra had FDA orphan-drug designation for prevention of acute GvHD and EMA orphan designation and ATMP certification. These designations are not marketing approvals. Accelerated or conditional approval pathways were possible but not assured.
- Key risks: Continued operating losses, no product revenue, dependence on additional financing and on Allocetra; clinical and regulatory uncertainty; manufacturing scale-up, contamination and blood-supply risks; reliance on third parties; competition and intellectual-property risks; and foreign-exchange exposure. The company had not hedged currency risk.
- Contingencies: The company disclosed approximately $3,973 of contingent Israel Innovation Authority grant repayment obligations at year-end, generally payable as 3%–5% royalties on qualifying sales until grants plus interest are repaid. Transfers of supported technology outside Israel may require approval and could trigger additional payments. Routine legal proceedings were not expected by management to have a significant financial effect.
- Other unusual items: Share-based compensation expense rose to $1,009 from $121. A $222 provision for uncertain tax-withholding positions was included in accrued liabilities. Management reported effective disclosure controls and internal control over financial reporting at year-end; the filing did not include auditor attestation of internal controls.
Important facts for investors to verify
- Reconcile the private-placement share count and proceeds, merger closing date, post-merger ownership percentages, and reported share counts, which reflect different transaction and share-adjustment bases.
- Confirm current cash, subsequent financing, actual runway and progress against planned clinical-trial timelines; the runway estimate was based on the company’s then-current operating plan.
- Review complete clinical-trial protocols, patient-level results, comparator methodology and regulatory correspondence; distinguish company-reported early findings from established efficacy.
- Assess the potential cost and timing of clinical manufacturing scale-up, and confirm IIA approval or payment requirements for any contemplated licensing, manufacturing or technology transfer outside Israel.
- Review the audited statements and notes alongside the unaudited merger pro forma, including lease-obligation disclosures and the differing placement figures.